Translational nanoparticle engineering for cancer vaccines.
Translational nanoparticle engineering for cancer vaccines.
复制标题
DOI：
10.1080/2162402x.2017.1290036
复制
发表时间：
2017
期刊：
影响因子：
7.2
通讯作者：
Mitchell DA
中科院分区：
文献类型：
--
作者：
Grippin AJ;Sayour EJ;Mitchell DA
传统的癌症治疗仍然不足以治疗许多耐药肿瘤。癌症疫苗试图通过激活患者的免疫系统来消除肿瘤细胞，而没有全身化疗和放疗的毒性来克服这种耐药性。纳米颗粒（NPs）作为可定制的免疫刺激载体来保护和递送抗原是有希望的。尽管许多NP疫苗已在临床前环境中进行了研究，但少数已进入临床应用，并且仍有少数已证明临床益处。本综述结合了在早期临床试验中评价的NP疫苗的观察结果，为下一代基于NP的癌症疫苗提出建议。
Conventional cancer treatments remain insufficient to treat many therapy-resistant tumors. Cancer vaccines attempt to overcome this resistance by activating the patient's immune system to eliminate tumor cells without the toxicity of systemic chemotherapy and radiation. Nanoparticles (NPs) are promising as customizable, immunostimulatory carriers to protect and deliver antigen. Although many NP vaccines have been investigated in preclinical settings, a few have advanced into clinical application, and still fewer have demonstrated clinical benefit. This review incorporates observations from NP vaccines that have been evaluated in early phase clinical trials to make recommendations for the next generation of NP-based cancer vaccines.